Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine (TCM), Shanghai, China.
Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (TCM), Shanghai, China.
DNA Cell Biol. 2021 Feb;40(2):405-413. doi: 10.1089/dna.2020.6232.
The aim of this study is to study the relationship between programmed cell death-1 ligand (PD-L1) and human epidermal growth receptor 2 (HER2) and the clinical-pathological features of gastric cancer (GC) and its predictive effect on the prognosis of gastric cancer (GC) patients. A retrospective analysis was performed on 113 patients undergoing GC surgery. The expression of PD-L1 and HER2 in GC and paired adjacent nontumor tissues was detected by immunohistochemistry or fluorescence hybridization, and the relationships between PD-L1 and HER2 expression and clinical-pathological features and survival were analyzed by chi-square analysis, Pearson analysis, logistic regression analysis, Kaplan-Meier analysis, and Cox regression model. PD-L1 and HER2 were expressed in tumor tissues, but not in adjacent nontumor tissues. There was no correlation between the expression of PD-L1 and HER2. The expression of PD-L1 in GC was closely related to gender ( = 0.019), regional lymph node ( = 0.006), metastasis ( = 0.033), and survival status ( = 0.033), while HER2 was closely related to tumor differentiation ( = 0.033), regional lymph node ( = 0.016), and tumor-node-metastasis (TNM) stage ( = 0.036). The survival time of PD-L1-positive patients was longer than that of PD-L1-negative patients ( = 0.020). The expression of HER2 showed no difference in overall survival ( = 0.125). Multivariate analysis suggested that the TNM stage ( = 0.001) and PD-L1 expression ( = 0.047) were independent prognostic factors for survival time of GC. The expression of PD-L1 has biological significance in GC, which is closely related to the clinical-pathological characteristics and prognosis of GC patients.
本研究旨在探讨程序性死亡配体 1（PD-L1）与人类表皮生长因子受体 2（HER2）与胃癌（GC）的临床病理特征及其对 GC 患者预后的预测作用。对 113 例行 GC 手术的患者进行回顾性分析。采用免疫组织化学或荧光杂交法检测 GC 及配对癌旁非肿瘤组织中 PD-L1 和 HER2 的表达，采用卡方检验、Pearson 分析、logistic 回归分析、Kaplan-Meier 分析和 Cox 回归模型分析 PD-L1 和 HER2 表达与临床病理特征及生存的关系。PD-L1 和 HER2 在肿瘤组织中表达，而在癌旁非肿瘤组织中不表达。PD-L1 和 HER2 的表达无相关性。GC 中 PD-L1 的表达与性别（ = 0.019）、区域淋巴结（ = 0.006）、转移（ = 0.033）和生存状态（ = 0.033）密切相关，而 HER2 与肿瘤分化（ = 0.033）、区域淋巴结（ = 0.016）和肿瘤-淋巴结-转移（TNM）分期（ = 0.036）密切相关。PD-L1 阳性患者的生存时间长于 PD-L1 阴性患者（ = 0.020）。HER2 的表达在总生存时间上无差异（ = 0.125）。多因素分析提示 TNM 分期（ = 0.001）和 PD-L1 表达（ = 0.047）是 GC 患者生存时间的独立预后因素。PD-L1 在 GC 中具有生物学意义，与 GC 患者的临床病理特征和预后密切相关。
